This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

This research investigates taste alterations experienced by cancer patients during chemotherapy and radiotherapy. Using electrogustometry and flavour profile analysis, the study measures and categorizes changes in taste perception to guide the development of tailored food products that improve nutrition, comfort, and quality of life for people undergoing cancer treatment.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

This research investigates how cells repair dangerous DNA double-strand breaks through the non-homologous end joining pathway. By identifying key proteins involved in this error-prone repair process, the work reveals new opportunities to sensitise cancer cells to radiation and chemotherapy, potentially improving treatment outcomes for aggressive cancers.

This research links two major treatment challenges in childhood acute lymphoblastic leukemia through ferroptosis, a lipid oxidation process regulated by selenium. By targeting selenium uptake in the brain and after chemotherapy, the work identifies potential new therapeutic strategies to reduce cancer cell survival and improve long-term treatment outcomes.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.